相关实验视频
Updated: Sep 11, 2025

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
18.0K
在现实世界HIV感染者的比克特格拉维尔的群体药理动力学
Pierre Ekobena1,2, Myriam Briki1,3, Kim Dao1
1Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
The Journal of antimicrobial chemotherapy
|August 13, 2025
概括
这项研究描述了艾滋病毒感染者的比克特格拉维尔药理学,发现年龄和体重有轻微的影响. 通常不需要对比克特格拉维尔进行常规治疗药物监测,但在特定情况下可能有所帮助.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 艾滋病毒/艾滋病 治疗
背景情况:
- 比克特格拉维尔是一种广泛用于HIV治疗的整合酶链转移抑制剂.
- 它在艾滋病毒感染者 (PWH) 中的真实世界药理动力学 (PK) 概况仍然在很大程度上未被描述.
- 了解bictegravir PK对于优化治疗和管理潜在的药物相互作用至关重要.
研究的目的:
- 在PWH中描述比克特格拉维尔的群体药理动力学 (PK) 概况.
- 为了确定潜在的共同变量,如年龄和体重,影响bictegravir disposition.
- 在现实环境中评估已确定PK变异的临床意义.
主要方法:
- 使用非线性混合效应模型 (Monolix®) 进行人口PK分析.
- 在瑞士 (2019年7月至2024年7月) 的572个PWH中利用了708个稳定状态血度.
- 从瑞士艾滋病毒队列研究 (SHCS) 收集的人口统计,临床和联合治疗数据.
主要成果:
- 一个具有第一阶吸收和排泄的单间模型准确地描述了bictegravir PK.
- 年龄和体重被确定为影响比克特格拉维尔清除量的显著共变量.
- 由于年龄和体重所观察到的PK变化是轻微的,并非临床显著,不需要干预.
结论:
- 对比克特格拉维尔的常规治疗药物监测 (TDM) 具有有限的价值,因为它具有有利的PK/安全性.
- 在特定情况下,TDM可能是有益的:怀疑耐药性,不坚持,特殊人群 (肥胖者,孕妇) 或监测药物相互作用.
相关概念视频
Retrovirus Life Cycles
46.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.8K
Bioavailability: Overview
3.1K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.1K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
80
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
80
Pharmacokinetics: Overview
7.2K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
7.2K
Analysis of Population Pharmacokinetic Data
383
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
383

